Navigation Links
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
Date:4/9/2009

BEIJING, April 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's unaudited financial results for the three and twelve month periods ended December 31, 2008.

    Full Year 2008 Financial Highlights
    -- Record full year 2008 sales increasing 39% year-over-year to $46.5
       million
    -- Sold 6.93 million doses of Healive(R) in 2008, up from 5.12 million in
       2007
    -- Record full year net income growing of 5% to $8.01 million
    -- Full year EPS is $0.19
    -- Cash and cash equivalents increased 93% to $32.9 million, compared to
       the beginning of 2008, due to an increase in operation profits,
       improved accounts receivable collection and raising capital.

    Business Highlights
    -- In 2008, Sinovac initiated the development program of a vaccine against
       enterovirus 71 (EV 71), which causes hand, foot and mouth disease.
       Development is progressing on schedule and good achievements have been
       made to date.  Sinovac expects to file clinical trial application with
       China SFDA in 2009.
    -- Recognizing the sizeable market opportunity for animal vaccines,
       Tangshan Yian, Sinovac's wholly owned subsidiary, is focusing on the
       animal vaccine business to help drive growth.  In January 2009, the
       Company obtained approval from China's Ministry of Agriculture to
       conduct field trials of internally developed inactivated animal rabies
       vaccine.  Sinovac expects the field trials to take approximately nine
       months to complete and to launch the vaccine in China's veterinary
       market in 2010.
    -- Sinovac completed the pre-clinical trial for the Japanese encephalitis
       vaccine in 2008 and filed the clinical trial application with SFDA in
 
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
3. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
4. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
5. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
6. Sinovac Releases Statement on Healive Vaccine Suspension
7. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
8. Sinovac Named to Deloitte Technology Fast 50 China
9. Sinovac to Participate in Two Upcoming Investor Conferences
10. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
11. Sinovac Biotech Holds 2007 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... MA (PRWEB) October 27, 2014 ... profit. SoundConnect , an industry leading unified ... its partners and agents to deliver cloud-based audio ... accelerate growth opportunities. , With SoundConnect’s Q4 ... every twenty-five video and/or web conferencing licenses sold, ...
(Date:10/27/2014)... Mass. , Oct. 27, 2014 ... "Company"), a worldwide leader in the development and ... the life sciences research market, today announced that ... presented a novel, accurate, highly reproducible, and robust ... – routine high-throughput protein analysis on small needle ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4SoundConnect Unveils Q4 Partner Incentives 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... At the 44th Annual Meeting of,the American Society ... the potential utility of Zevalin(R) (Ibritumomab,Tiuxetan) radioimmunotherapy as ... chemotherapy in the treatment of non-Hodgkin,s,lymphoma (NHL). Cell ... markets,Zevalin in the United States., "These two ...
... CITY, China, May 30 /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, ... which develops, manufactures, and markets generic and branded,bio-pharmaceutical ... 30, 2008,it closed its recently announced financing, issuing ... price of $2.00 per share and three-year warrants,to ...
... PRINCETON, N.J., May 30 Pharmacopeia (Nasdaq:,PCOP), an ... small,molecule therapeutics, announced today that it is implementing ... its resources on the company,s clinical,and later-stage discovery ... approximately 15 percent through attrition and,termination of positions ...
Cached Biology Technology:Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 2Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 3Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma 4China Pharma Holdings, Inc. Closes $10 Million Financing 2China Pharma Holdings, Inc. Closes $10 Million Financing 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 2Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 3Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs 4
(Date:10/29/2014)... in New York City on September 19, 2014, leading ... Society Professor of Genome Sciences and Medicine at the ... of Philosophy of Tel Aviv University, was awarded the ... In addition to her honorary degree from TAU, Prof. ... School of Medicine, and for the past 18 years ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... Genomics of the Kidney consortium ( CAGEKID ) ... exposure to aristolochic acid, an ingredient in some ... Communications , have important implications for public health. ... every year, and in Central Europe incidence rates ... International Cancer Genome Consortium (ICGC), has been studying ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Kidney cancer in Central Europe 2
... amphibians developed the ability to feed on land before ... University report this week in the Proceedings of the ... on analysis of the skulls of the first amphibians, ... ancestors. The shapes of the junctions between adjacent skull ...
... Atlantic Ocean doesn't receive the mother lode of fixed nitrogen, ... for fathom, the Pacific and Indian oceans experience twice the ... the Jan. 11 issue of Nature. , The title of ... for N2 Fixation in all the Wrong Places." ...
... Why have large outbreaks of Ebola virus killed tens ... decade? Observations published in the May issue of The ... be amplified by Ebola transmission between ape social groups. ... control the devastating impact of Ebola on wild apes. ...
Cached Biology News:Ancient amphibians evolved a bite before migrating to dry land 2New findings blow a decade of assumptions out of the water 2New findings blow a decade of assumptions out of the water 3Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Potassium Channel kv3.2...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
MAb to Vasopressin Preservative: NaN3...
Biology Products: